Skip to main content
BDTX
NASDAQ Life Sciences

Black Diamond Therapeutics Reports Strong 2025 Net Income, $128.7M Cash Extending Runway to 2H 2028, and Positive Clinical Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.14
Mkt Cap
$124.775M
52W Low
$1.195
52W High
$4.94
52W Position info
79% above low
Off High info
57% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BDTX sits 79% above its 52-week low of $1.195.

Summary

Black Diamond Therapeutics announced a significant financial turnaround for 2025 with a net income of $22.4 million, a cash position of $128.7 million extending its runway into the second half of 2028, and positive clinical data for silevertinib.


Key Events · Earnings and Guidance · BDTX

  • Strong 2025 Financial Performance

    Reported a net income of $22.4 million for the full year 2025, a significant turnaround from a $69.7 million net loss in 2024, largely due to $70 million in license revenue.

  • Extended Cash Runway

    Ended 2025 with $128.7 million in cash, cash equivalents, and investments, which is expected to fund operations into the second half of 2028.

  • Positive Silevertinib Clinical Data

    Initial Phase 2 data for silevertinib in non-classical EGFRm NSCLC patients showed a 60% Objective Response Rate and 86% CNS Objective Response Rate.

  • Upcoming Clinical Milestones

    Anticipates presenting updated Phase 2 NSCLC data (including DOR and PFS) and initiating a randomized Phase 2 trial in EGFR-altered GBM in Q2 2026.


Analysis · BDTX · Life Sciences

This 8-K filing signals a major positive shift for Black Diamond Therapeutics. The company reported a net income of $22.4 million for 2025, a substantial improvement from the prior year's loss, primarily driven by $70 million in license revenue. Critically, the cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, are projected to fund operations into the second half of 2028, providing a long and stable financial runway for a clinical-stage biotech. This strong financial position significantly de-risks the company's operations. Furthermore, the company provided positive clinical updates for silevertinib, including a 60% Objective Response Rate and 86% CNS Objective Response Rate in non-classical EGFRm NSCLC patients, with further Phase 2 data and a new randomized Phase 2 trial in GBM expected in Q2 2026. The combination of robust financials and promising clinical progress makes this a highly important and positive development for investors.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDTX was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.8M. The 52-week trading range was $1.20 to $4.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDTX - Latest Insights

BDTX
Nov 10, 2026, 6:31 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.97 info
Change: -$0.0296 (-1%) info
Market Cap: $106.864M info
BDTX
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $1.97 info
Change: -$0.0296 (-1%) info
Market Cap: $106.864M info
BDTX
Nov 10, 2026, 6:28 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $1.97 info
Change: -$0.0496 (-2%) info
Market Cap: $106.864M info
BDTX
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.97 info
Change: +$0.0204 (+1%) info
Market Cap: $106.864M info
BDTX
May 21, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.19
Real-time Price: $1.97 info
Change: -$1.22 (-38%) info
Market Cap: $106.864M info